BRD4 and Hepatic fibrosis: Anti‐cancer drugs, including Vorinostat and BRD4 inhibitors, have been used as cellular differentiating agents for treatment of several types of cancer;[49] and Vorinostat can induce mesenchymal cell differentiation.[50] Our findings indicate that epigenomic modifying drugs should be given serious consideration as treatments of liver fibrosis and could form part of a new generation of anti‐fibrotic agents that also promote liver parenchymal cell regeneration.